In contrast to the conventional drug L-thyroxine for curing hypothyroidism, YJT has a unique efficacy for attenuating systematic inflammatory responses via the suppression of intestinal LPS–TLR4 and peptidoglycan–Nod2/Pglyrp1 signaling pathways (Fig. 7). This evidence concerns the gene PGLYRP1 and hypothyroidism.